Turkiye Klinikleri Cardiovascular Sciences

.: ORIGINAL RESEARCH
Sakubitril/Valsartan Kullanımının Kliniğe ve Laboratuvar Bulgularına Etkilerinin, İskemik ve Non-İskemik Kalp Yetersizliği Hastalarında Karşılaştırmalı Olarak Değerlendirilmesi
The Effect of Sacubitril/Valsartan on Clinical and Laboratory Findings Comparatively in Ischemic and Non-Ischemic Heart Failure Patients
Tuğba KEMALOĞLU ÖZa, Tarık KIVRAKb, Tayfun GÜROLc, Regayip ZEHİRd, Özer SOYLUc, Bahadır DAĞDEVİRENc
aKardiyoloji Kliniği, İstanbul Medipol Üniversitesi Çamlıca Hastanesi,
bKardiyoloji ABD, Fırat Üniversitesi Hastanesi,
cKardiyoloji Kliniği, Bahçeşehir Üniversitesi Göztepe Medical Park Hastanesi,
dKardiyoloji Kliniği, Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi, İstanbul, TÜRKİYE
Turkiye Klinikleri J Cardiovasc Sci. 2019;31(3):135-42
doi: 10.5336/cardiosci.2019-66657
Article Language: TR
Full Text
ÖZET
 Amaç: Sakubitril/valsartan tedavisinin, enalaprile kıyasla düşük ejeksiyon fraksiyonlu kalp yetersizliği (DEF-KY) hastalarında hastaneye yatış ve mortalite riskini azalttığı ve yaşam kalitesini artırdığı gösterilmiştir, ancak bugüne kadar ülkemizde yapılmış, sakubitril/valsartanın klinik bulgulara ve laboratuvar sonuçlarına olan etkilerini gösteren çalışma bulunmamaktadır. Biz çalışmamızda, sakubitril/ valsartan tedavisinin kliniğe ve laboratuvar bulgularına olan etkilerini hem iskemik hem de non-iskemik DEF-KY hastalarında karşılaştırmalı olarak araştırmayı hedefledik. Gereç ve Yöntemler: Çalışmamıza, 18 yaşından büyük, KY kılavuzlarına göre sakubitril/valsartan tedavisi başlama endikasyonu olan hastalar dâhil edildi. Tüm hastalardan tedavi başlamadan önce ve tolere edilebilen maksimal doz sakubitril/valsartan tedavisinin 6. ayında olmak üzere iki kez ayrıntılı öykü alındı, tüm sistem fizik muayene yapıldı ve elektrokardiyogram çekildi. Venöz kanda sodyum (Na), potasyum (K), kreatinin ve NT-ProBNP düzeylerine bakıldı. Tedavi öncesi ve sonrası bulgular karşılaştırıldı. Bulgular: Çalışmaya başlangıçta 150 hasta katıldı. Bu hastalardan 19'u takip süresini tamamlayamadığı için çalışma dışı bırakıldı ve toplamda 71'i iskemik, 56'sı ise non-iskemik KY hastası olmak üzere 127 hasta (%27,6'sı kadın) çalışmaya dâhil edildi. Her iki grupta da sistolik ve diyastolik kan basıncı, dakikadaki kalp hızı, NT-proBNP ve Na düzeyi ve haftalık furosemid ihtiyacında istatistiksel olarak anlamlı azalma gözlendi. Glomerüler filtrasyon hızı (GFH)'nda anlamlı değişiklik olmazken, kreatinin ve potasyum (K) düzeylerinde istatistiksel olarak anlamlı artış tespit edildi. Sonuç: Bu çalışmanın sonuçları göstermiştir ki sakubitril/valsartan, hem iskemik hem de non-iskemik DEF-KY'de benzer etkiler yaratmakta, her iki grupta da hastaların laboratuvar ve klinik bulgularında belirgin düzelme, semptomlarında rahatlama, haftalık furosemid ihtiyacında azalma ve kalp hızında düşüş sağlamaktadır. Bununla birlikte, yan etkiler olarak semptomatik hipotansiyon, hiperpotasemi ve GFH düşüşü açısından dikkatli olunmalıdır.

Anahtar Kelimeler: Kalp yetersizliği; LCZ 696; Kalp yetersizliği, sistolik; tedavi sonucu
ABSTRACT
 Objective: Sacubitril/valsartan treatment has been shown to reduce the risk of hospitalization and mortality and to improve the quality of life in patients with symptomatic heart failure (HF) with reduced ejection fraction (HFrEF) compared to enalapril. To the best of our knowledge, no data have compared the ischemic and non-ischemic HRrEF groups in Turkey. This study comparatively investigated the effects of sacubitril/valsartan on clinical and laboratory findings in both ischemic and non-ischemic HF groups. Material and Methods: This study included patients with an indication for sacubitril/valsartan treatment initiation according to the HF guidelines. All patients underwent detailed histories, physical examinations, electrocardiograms, and laboratory tests, including sodium (Na), potassium(K), creatinine, and NT-proBNP, both before and 6 months after the treatment. We then compared the pre and post treatment findings. Results: A total of 127 patients (27.6% female), including 71 in the ischemic HF group and 56 in the non-ischemic HF group were enrolled the study. In both groups, systolic and diastolic blood pressures, heart rate per minute, NT-proBNP and sodium levels and weekly furosemide doses decreased significantly after sacubitril/valsartan treatment. While we observed no significant change in the glomerular filtration rate, we saw a statistically significant increase in creatinine and potassium levels. Conclusion: This study's results show the efficacy of sacubitril/valsartan in improving symptoms and cardiac biomarkers while reducing the need for diuretic therapy and heart rate in both ischemic and non-ischemic HFrEF patients. On the other hand, some complications (renal dysfunction, symptomatic hypotension and hyperkalemia) should be considered.

Keywords: Heart failure; LCZ 696; Heart failure, systolic; treatment outcome
REFERENCES:
  1. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail. 2011;4(4):396-403. [Crossref]  [PubMed] 
  2. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. [Crossref]  [PubMed] 
  3. McMurray J, Struthers AD. Significance of atrial natriuretic factor in chronic heart failure. Br J Hosp Med. 1988;40(1):55-7.
  4. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JM, Dargie HJ, et al. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet. 1989;2(8663):591-3. [Crossref] 
  5. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000;36(2):479-86. [Crossref] 
  6. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615-20. [Crossref] 
  7. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920-6. [Crossref]  [PubMed] 
  8. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990-7. [Crossref]  [PubMed] 
  9. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. [Crossref]  [PubMed] 
  10. DeVore AD, Hill CL, Thomas L, Sharma PP, Albert NM, Butler J, et al. Patient, provider, and practice characteristics associated with sacubitril/valsartan use in the United States. Circ Heart Fail. 2018;11(9):e005400. [Crossref] 
  11. De Vecchis R, Ariano C, Di Biase G, Noutsias M. Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction: a retrospective cohort study. Herz. 2019;44(5):425-432. [Crossref]  [PubMed] 
  12. Vicent L, Esteban-Fernandez A, Gomez-Bueno M, De-Juan J, Diez-Villanueva P, Iniesta AM, et al. Sacubitril/valsartan in daily clinical practice: data from a prospective registry. J Cardiovasc Pharmacol. 2019;73(2):118-24. [Crossref]  [PubMed] 
  13. Lourenco C, Saraiva F, Martins H, Baptista R, Costa S, Coelho L, et al. [Ischemic versus non-ischemic cardiomyopathy--are there differences in prognosis? Experience of an advanced heart failure center]. Rev Port Cardiol. 2011;30(2):181-97.
  14. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9(3):e002744. [Crossref] 
  15. Jhund PS, Fu M, Bayram E, Chen CH, Chen CH, Negrusz-Kawecka M, et al; PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576-84. [Crossref]  [PubMed]  [PMC] 
  16. Bohm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38(15):1132-43. [Crossref]  [PubMed]  [PMC] 
  17. Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7(6):457-65. [Crossref]  [PubMed] 
  18. de Diego C, Gonzalez-Torres L, Nunez JM, Centurion Inda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018;15(3):395-402. [Crossref]  [PubMed] 
  19. Adie S, Bitar A, Hanigan S, Pogue K, Koelling T, Dorsch M. Real-world prevalence of adverse events after initiating sacubitril/valsartan compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure. J Card Fail. 2019;25(5):412-13. [Crossref]  [PubMed] 
  20. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heartfailure. JACC Heart Fail. 2018;6(6):489-98. [Crossref]  [PubMed] 
  21. Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018;3(6):498-505. [Crossref]  [PubMed]  [PMC] 
  22. Ayalasomayajula S, Schuehly U, Pal P, Chen F, Zhou W, Sunkara G, et al. Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. Br J Clin Pharmacol. 2018;84(5):926-36. [Crossref]  [PubMed]  [PMC] 
  23. Murray G, Barrett M, Earls S, Hammond M, Campbell P, O'Hanlon R, et al. The use of sacubitril/valsartan: a real world experience in a high volume specialist heart failure service. Heart. 2017;103(Suppl 6):A8.3-A9.
  24. Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21(5):588-97. [Crossref]  [PubMed]  [PMC] 
  25. Pugliese NR, Fabiani I, Zywicki V, Mazzola M, D'Agostino A, Galeotti GG, et al. Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ?35. Curr Med Res Opin 2019;35(Suppl 3):13-8. [Crossref]  [PubMed] 
  26. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond). 1996;91(3):283-91. [Crossref]  [PubMed] 
  27. Nougue H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598-605. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com